16 research outputs found
Median baseline parameters across the total cohort and male and female populations.
<p>Median baseline parameters across the total cohort and male and female populations.</p
Prevalence data and standard error per participating country.
<p>Graphs depicting (A) dyslipidemia prevalence, (B) hypertension prevalence, (C) obesity (defined by BMI ≥30 kg/m<sup>2</sup>) prevalence, (D) abdominal obesity prevalence, (E) diabetes prevalence, and (F) smoking prevalence. Overall prevalence is shown by a solid line.</p
Overall cohort prevalence per investigated cardiovascular risk factor.
<p>Graphs to show the difference in total cohort prevalence data for each risk factor (dyslipidemia, hypertension, diabetes, obesity (defined by BMI ≥30 kg/m<sup>2</sup>), abdominal obesity, and smoking) by (A) age, (B) gender, and (C) location.</p
Overall prevalence of cardiovascular risk factors across all participating countries.
<p>Graph to show the overall prevalence and standard error of dyslipidemia, hypertension, obesity (defined by BMI ≥30 kg/m<sup>2</sup>), abdominal obesity, diabetes, and smoking across the AfME region.</p
Proportion of outpatients presenting with one or more cardiovascular risk factors.
<p>Graph to show the percentage of outpatients presenting with 1–6 CV risk factors. Risk factors: dyslipidemia prevalence, hypertension prevalence, obesity (defined by BMI ≥30 kg/m<sup>2</sup>) prevalence, abdominal obesity prevalence, diabetes prevalence, and smoking prevalence.</p
Comparison of atrial fibrillation risk factors between sexes.
<p>Comparison of atrial fibrillation risk factors between sexes.</p
Baseline characteristics of study patients with non-valvular atrial fibrillation<sup>*</sup>.
<p>Baseline characteristics of study patients with non-valvular atrial fibrillation<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175405#t001fn002" target="_blank">*</a></sup>.</p
Sex differences in outcome events at 12 months follow-up in the entire cohort according to the reasons for emergency room visit (N = 2043).
<p>Sex differences in outcome events at 12 months follow-up in the entire cohort according to the reasons for emergency room visit (N = 2043).</p
Comparison of differences in CHADS<sub>2</sub> with warfarin and antiplatelet therapy between sexes (n = 1776).
<p>Comparison of differences in CHADS<sub>2</sub> with warfarin and antiplatelet therapy between sexes (n = 1776).</p
Baseline characteristics of patients stratified by gender (n = 7930).
<p>Figures in parentheses are percentages and continuous variables are shown as mean±SD.</p><p>Abbreviations: SD, standard deviation; BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CHF, congestive heart failure; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina.</p>*<p>Killip class (scale I–IV) a system used to stratify the severity of left ventricular dysfunction and determines clinical status of patients post myocardial infarction (MI).</p><p>Killip classification:</p><p>Class 1: No rales, no 3rd heart sound.</p><p>Class 2: Rales in <1/2 lung field or presence of a 3rd heart sound.</p><p>Class 3: Rales in >1/2 lung field–pulmonary edema.</p><p>Class 4: Cardiogenic shock–determined clinically.</p